Affordable Access

Polymorphism in IgG Fc receptor gene FCGR3A and response to infliximab in Crohn's disease: a subanalysis of the ACCENT I study.

Authors
Publication Date
Keywords
  • Adolescent
  • Adult
  • Aged
  • Antibodies
  • Monoclonal/Therapeutic Use
  • Base Sequence
  • Crohn Disease/Genetics/Immunology/Therapy
  • Dna Primers/Genetics
  • Female
  • Genotype
  • Heterozygote
  • Homozygote
  • Humans
  • Male
  • Middle Aged
  • Pharmacogenetics
  • Polymorphism
  • Single Nucleotide
  • Receptors
  • Igg/Genetics
  • Human Health Sciences :: Gastroenterology & Hepatology [D08]
  • Sciences De La Santé Humaine :: Gastroentérologie & Hépatologie [D08]
Disciplines
  • Biology
  • Medicine

Abstract

Recently, it has been shown that FCGR3A-158 gene polymorphism is associated with biological and possibly clinical response to infliximab in Crohn's disease. We further assessed this association in a subset of 344 patients from the large and well-defined cohort of 573 patients with Crohn's disease from the ACCENT I study. No association could be observed between FCGR3A-158 gene polymorphism and the clinical response to infliximab, which was primarily defined as a decrease of >or=70 points in the Crohn's disease activity index or clinical remission (Crohn's disease activity index <150). We did, however, confirm a trend towards a greater decrease in C-reactive protein after infliximab in V/V homozygotes as compared with V/F heterozygotes and F/F homozygotes (-79.4, -76.5, and -64.3%, respectively, at week 6; P=0.085; one-tailed P=0.043). This finding has no immediate clinical impact but may enhance the understanding of the complex mechanisms of action of anti-tumor necrosis factor agents in Crohn's disease.

There are no comments yet on this publication. Be the first to share your thoughts.